- Home
- AMPX vs FULC Comparison
AMPX vs FULC Comparison
Compare AMPX & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPX
- FULC
- Stock Information
- Founded
- AMPX 2008
- FULC 2015
- Country
- AMPX United States
- FULC United States
- Employees
- AMPX N/A
- FULC N/A
- Industry
- AMPX Industrial Machinery/Components
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- AMPX Miscellaneous
- FULC Health Care
- Exchange
- AMPX Nasdaq
- FULC Nasdaq
- Market Cap
- AMPX 261.0M
- FULC 210.9M
- IPO Year
- AMPX N/A
- FULC 2019
- Fundamental
- Price
- AMPX $3.01
- FULC $3.85
- Analyst Decision
- AMPX Strong Buy
- FULC Hold
- Analyst Count
- AMPX 8
- FULC 9
- Target Price
- AMPX $8.63
- FULC $7.63
- AVG Volume (30 Days)
- AMPX 3.0M
- FULC 368.1K
- Earning Date
- AMPX 03-20-2025
- FULC 02-25-2025
- Dividend Yield
- AMPX N/A
- FULC N/A
- EPS Growth
- AMPX N/A
- FULC N/A
- EPS
- AMPX N/A
- FULC N/A
- Revenue
- AMPX $17,480,000.00
- FULC $80,871,000.00
- Revenue This Year
- AMPX $132.63
- FULC $2,823.78
- Revenue Next Year
- AMPX $214.27
- FULC N/A
- P/E Ratio
- AMPX N/A
- FULC N/A
- Revenue Growth
- AMPX 196.22
- FULC 2987.86
- 52 Week Low
- AMPX $0.61
- FULC $2.86
- 52 Week High
- AMPX $4.21
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- AMPX 43.80
- FULC 47.75
- Support Level
- AMPX $3.28
- FULC $3.64
- Resistance Level
- AMPX $3.65
- FULC $3.94
- Average True Range (ATR)
- AMPX 0.28
- FULC 0.18
- MACD
- AMPX -0.06
- FULC 0.02
- Stochastic Oscillator
- AMPX 8.49
- FULC 84.21
About AMPX Amprius Technologies Inc.
Amprius Technologies Inc is engaged in the production of silicon anodes for high energy density lithium-ion batteries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. All of its revenues is geographically earned in the United States.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.